• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

ALK-Abelló

241.60 DKK

-0.98 %

Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.98 %
-9.24 %
+17.40 %
+6.90 %
+5.69 %
+27.29 %
+224.51 %
+57.09 %
+600.29 %

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Read more
Market cap
53.83B DKK
Turnover
12.11M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

18.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release04.06.2026 klo 09.30

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

ALK-Abelló
Regulatory press release01.06.2026 klo 22.20

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Press release29.05.2026 klo 17.27

ALK to present at the Jefferies Global Healthcare Conference in New York

ALK-Abelló

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release04.05.2026 klo 13.16

Three-month interim report (Q1) 2026 (unaudited)

ALK-Abelló
Regulatory press release04.05.2026 klo 13.08

ALK upgrades its full-year outlook

ALK-Abelló
Press release28.04.2026 klo 17.13

Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026

ALK-Abelló
Regulatory press release20.04.2026 klo 15.33

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

ALK-Abelló
Press release15.04.2026 klo 13.07

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK-Abelló
Regulatory press release08.04.2026 klo 23.37

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Regulatory press release01.04.2026 klo 11.05

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ALK-Abelló
Press release31.03.2026 klo 10.01

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

ALK-Abelló
Regulatory press release16.03.2026 klo 19.37

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

ALK-Abelló
Press release04.03.2026 klo 12.20

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

ALK-Abelló
Regulatory press release20.02.2026 klo 15.54

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

ALK-Abelló
Regulatory press release20.02.2026 klo 08.31

Henriette Mersebach to step down as ALK’s head of R&D

ALK-Abelló
Regulatory press release20.02.2026 klo 08.17

Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin

ALK-Abelló
Press release13.02.2026 klo 13.16

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

ALK-Abelló
Regulatory press release29.01.2026 klo 17.15

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children

ALK-Abelló
Press release08.01.2026 klo 18.17

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

ALK-Abelló
Press release22.12.2025 klo 17.13

ALK – Financial calendar for the 2026 financial year

ALK-Abelló